Benefits of Drug Combo in Myeloma Maintenance Shown in Relevant Subgroups

(MedPage Today) -- A post hoc analysis of the phase III AURIGA study showed that the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) for multiple myeloma in the post-transplant maintenance setting improved minimal residual disease...